Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar; Jesus D. Gonzalez-Lugo; Niyati Goradia; Radhika Gali; Lauren C. Shapiro; Kith Pradhan; Shafia Rahman; So Yeon Kim; Brian Ko; R. Alejandro Sica; Noah Kornblum; Lizamarie Bachier-Rodriguez; Margaret McCort; Sanjay Goel; Roman Perez-Soler; Stuart Packer; Joseph Sparano; Benjamin Gartrell; Della Makower; Yitz D. Goldstein; Lucia Wolgast; Amit Verma; Balazs Halmos

doi:10.1016/j.ccell.2021.06.002

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar, Jesus D. Gonzalez-Lugo, Niyati Goradia, Radhika Gali, Lauren C. Shapiro, Kith Pradhan, Shafia Rahman, So Yeon Kim, Brian Ko, R. Alejandro Sica, Noah Kornblum, Lizamarie Bachier-Rodriguez, Margaret McCort, Sanjay Goel, Roman Perez-Soler, Stuart Packer, Joseph Sparano, Benjamin Gartrell, Della Makower, Yitz D. GoldsteinLucia Wolgast, Amit Verma, Balazs Halmos

Research output: Contribution to journal › Article › peer-review

238 Scopus citations

Abstract

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

Original language	English (US)
Pages (from-to)	1081-1090.e2
Journal	Cancer Cell
Volume	39
Issue number	8
DOIs	https://doi.org/10.1016/j.ccell.2021.06.002
State	Published - Aug 9 2021

Keywords

COVID-19
cancer
hematologi malignancies
vaccine

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2021.06.002

Cite this

Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., Rahman, S., Kim, S. Y., Ko, B., Sica, R. A., Kornblum, N., Bachier-Rodriguez, L., McCort, M., Goel, S., Perez-Soler, R., Packer, S., Sparano, J., Gartrell, B., Makower, D., ... Halmos, B. (2021). Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell, 39(8), 1081-1090.e2. https://doi.org/10.1016/j.ccell.2021.06.002

Thakkar, A, Gonzalez-Lugo, JD, Goradia, N, Gali, R, Shapiro, LC, Pradhan, K, Rahman, S, Kim, SY, Ko, B, Sica, RA , Kornblum, N, Bachier-Rodriguez, L, McCort, M, Goel, S, Perez-Soler, R, Packer, S, Sparano, J, Gartrell, B , Makower, D , Goldstein, YD , Wolgast, L , Verma, A & Halmos, B 2021, 'Seroconversion rates following COVID-19 vaccination among patients with cancer', Cancer Cell, vol. 39, no. 8, pp. 1081-1090.e2. https://doi.org/10.1016/j.ccell.2021.06.002

@article{3065977e79b940ef9e35d38614db6e1e,

title = "Seroconversion rates following COVID-19 vaccination among patients with cancer",

abstract = "As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.",

keywords = "COVID-19, cancer, hematologi malignancies, vaccine",

author = "Astha Thakkar and Gonzalez-Lugo, {Jesus D.} and Niyati Goradia and Radhika Gali and Shapiro, {Lauren C.} and Kith Pradhan and Shafia Rahman and Kim, {So Yeon} and Brian Ko and Sica, {R. Alejandro} and Noah Kornblum and Lizamarie Bachier-Rodriguez and Margaret McCort and Sanjay Goel and Roman Perez-Soler and Stuart Packer and Joseph Sparano and Benjamin Gartrell and Della Makower and Goldstein, {Yitz D.} and Lucia Wolgast and Amit Verma and Balazs Halmos",

note = "Funding Information: We acknowledge Albert Einstein Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund. A.T. A.V. and B.H. conceived and managed the study; J.D.G.-L. N.G. R.G. L.C.S. S.R. S.Y.K. B.K. R.A.S. N.K. L.B.-R. M.M. S.G. J.S. B.G. and D.M. participated in patient recruitment and data curation; K.P. oversaw data analyses; S.P. and R.P.-S. contributed to project administration; Y.D.G. and L.W. oversaw investigations. All authors contributed to writing the manuscript. A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests. Funding Information: We acknowledge Albert Einstein Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = aug,

day = "9",

doi = "10.1016/j.ccell.2021.06.002",

language = "English (US)",

volume = "39",

pages = "1081--1090.e2",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - Seroconversion rates following COVID-19 vaccination among patients with cancer

AU - Thakkar, Astha

AU - Gonzalez-Lugo, Jesus D.

AU - Goradia, Niyati

AU - Gali, Radhika

AU - Shapiro, Lauren C.

AU - Pradhan, Kith

AU - Rahman, Shafia

AU - Kim, So Yeon

AU - Ko, Brian

AU - Sica, R. Alejandro

AU - Kornblum, Noah

AU - Bachier-Rodriguez, Lizamarie

AU - McCort, Margaret

AU - Goel, Sanjay

AU - Perez-Soler, Roman

AU - Packer, Stuart

AU - Sparano, Joseph

AU - Gartrell, Benjamin

AU - Makower, Della

AU - Goldstein, Yitz D.

AU - Wolgast, Lucia

AU - Verma, Amit

AU - Halmos, Balazs

N1 - Funding Information: We acknowledge Albert Einstein Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund. A.T. A.V. and B.H. conceived and managed the study; J.D.G.-L. N.G. R.G. L.C.S. S.R. S.Y.K. B.K. R.A.S. N.K. L.B.-R. M.M. S.G. J.S. B.G. and D.M. participated in patient recruitment and data curation; K.P. oversaw data analyses; S.P. and R.P.-S. contributed to project administration; Y.D.G. and L.W. oversaw investigations. All authors contributed to writing the manuscript. A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests. Funding Information: We acknowledge Albert Einstein Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund. Publisher Copyright: © 2021 Elsevier Inc.

PY - 2021/8/9

Y1 - 2021/8/9

N2 - As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

AB - As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

KW - COVID-19

KW - cancer

KW - hematologi malignancies

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85109064956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109064956&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.06.002

DO - 10.1016/j.ccell.2021.06.002

M3 - Article

C2 - 34133951

AN - SCOPUS:85109064956

SN - 1535-6108

VL - 39

SP - 1081-1090.e2

JO - Cancer Cell

JF - Cancer Cell

IS - 8

ER -

Seroconversion rates following COVID-19 vaccination among patients with cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this